Novo Nordisk A/S
XBER:NOV
Novo Nordisk A/S
XBER:NOV
Price:
43.99
EUR
Market Closed
Market Cap:
€149.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Novo Nordisk A/S
XBER:NOV
|
DK |
|
Mrs. Bectors Food Specialities Ltd
NSE:BECTORFOOD
|
IN |
|
Vaishali Pharma Ltd
NSE:VAISHALI
|
IN |
|
H
|
Hibernia REIT PLC
LSE:HBRN
|
IE |
Multiples-Based Value
The Multiples-Based Value of one
NOV
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 43.99 EUR,
Novo Nordisk A/S
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOV Multiples-Based Value
LOCKED
Multiples Across Competitors
NOV Competitors Multiples
Novo Nordisk A/S Competitors
Novo Nordisk A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
XBER:NOV
|
1.1T EUR | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.4 | 16.6 | 7 | 8.7 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
87.4B GBP | 2.6 | 14.9 | 8.1 | 10.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
